UP5-C-Levo is a promising therapeutic candidate for the treatment of MDR and biofilm-associated infections. Its strong antibacterial and antibiofilm activity, combined with a favorable safety profile, supports further preclinical development and potential clinical translation.
Almaaytah et al. (Wed,) studied this question.